SCHEMBL14024944

SCHEMBL14024944

CC(C)CCCCNc1ncccn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HPGD P15428 1/20 0.49
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALOX12 P18054 1/20 0.36
PDPK1 O15530 1/20 0.36
SLC47A1 Q96FL8 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
DNM2 P50570 2/20 0.34
HRH4 Q9H3N8 1/20 0.34
EHMT2 Q96KQ7 1/20 0.34
EHMT1 Q9H9B1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13630788 0.94 ALDH1A1 (0.58) ALDH1A1HPGDHSP90AA1HSP90AB1TSHR
SCHEMBL18462183 0.86 ALDH1A1 (0.62) ALDH1A1HPGDMEN1NPC1RAB9A
SCHEMBL23081588 0.79 CYP2C19 (0.54) ALDH1A1TSHRNPC1RAB9AKDM4E
SCHEMBL658589 0.78 ALDH1A1 (0.62) ALDH1A1HPGDNPC1KMT2ADNM2
SCHEMBL10532570 0.76 ALDH1A1 (0.60) ALDH1A1HPGDKMT2AALOX12DNM2
SCHEMBL23610609 0.76 ALDH1A1 (0.60) ALDH1A1HPGDKMT2AALOX12DNM2
SCHEMBL6490227 0.75 ALDH1A1 (0.65) ALDH1A1HPGDNPC1DNM2HRH4
SCHEMBL23107659 0.74 ALDH1A1 (0.62) ALDH1A1HPGDTSHRKMT2AKDM4E
SCHEMBL8348328 0.74 ALDH1A1 (0.70) ALDH1A1HPGDHSP90AA1HSP90AB1
SCHEMBL15471171 0.73 ALDH1A1 (0.56) ALDH1A1HPGDSLC47A1DNM2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885HPGD 873/4885HSP90AA1 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.